ACA
PFE icon

Ackerman Capital Advisors’s Pfizer PFE Stock Holding History

Ackerman Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,056
Closed -$280K – 140
2020
Q3 		$280K Hold
8,056
– – 0.08% 84
2020
Q2 		$250K Hold
8,056
– – 0.07% 92
2020
Q1 		$249K Buy
+8,056
New +$275K 0.1% 73

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ackerman Capital Advisors's PFE Position: Q4 2020 in Review

Ackerman Capital Advisors sold out of Pfizer (PFE) in Q4 2020, closing a stake of 8,056 shares — an estimated $280K sold.

Ackerman Capital Advisors first reported a position in PFE in Q1 2020 and held it in 3 quarters. The position peaked at $280K in Q3 2020. 2,675 funds tracked by Wall St. Rank hold PFE as of Q4 2020.

  • Ackerman Capital Advisors reported no remaining Pfizer position as of Q4 2020 after selling out during the quarter.
  • Ackerman Capital Advisors sold 8,056 Pfizer shares in Q4 2020, an estimated $280K.
  • Ackerman Capital Advisors first reported a position in Pfizer in Q1 2020 and held it in 3 quarters.
  • Ackerman Capital Advisors's Pfizer position peaked at $280K in Q3 2020.
  • 2,675 funds tracked by Wall St. Rank held Pfizer as of Q4 2020.

Based on Ackerman Capital Advisors's 13F filing for Q4 2020, filed 1 Feb 2021.